Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 10/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490678 | 0.94 | MCL1 (0.41) | MCL1FFAR4PLA2G2ABCL2L1 | |
| SCHEMBL6489292 | 0.92 | MCL1 (0.38) | MCL1PLA2G2AALDH1A1MAPTHPGD | |
| SCHEMBL6491201 | 0.90 | MCL1 (0.43) | MCL1FFAR4PLA2G2ABCL2L1ALDH1A1 | |
| SCHEMBL6500004 | 0.87 | CYSLTR2 (0.37) | MCL1PLA2G2A | |
| SCHEMBL7195341 | 0.86 | DCTPP1 (0.31) | MCL1 | |
| SCHEMBL6497809 | 0.86 | MCL1 (0.41) | MCL1FFAR4FFAR1ALDH1A1MAPT | |
| SCHEMBL6501386 | 0.85 | MCL1 (0.48) | MCL1FFAR4FFAR1PLA2G2A | |
| SCHEMBL7195347 | 0.85 | GCG (0.32) | PDE4BPDE4D | |
| SCHEMBL6502360 | 0.84 | PABPC1 (0.39) | MCL1PLA2G2AALDH1A1 | |
| SCHEMBL6488122 | 0.81 | MCL1 (0.46) | MCL1FFAR4FFAR1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MCL1 806/4885FFAR4 960/4885FFAR1 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.